Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis

Ryan L. Hanson, Roger B. Brown, Maria M. Steele, Paul M. Grandgenett, James A. Grunkemeyer, Michael A Hollingsworth

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The MUC1 glycoprotein is overexpressed and aberrantly glycosylated in >90% of pancreatic ductal adenocarcinoma cases and impacts tumor progression by initiating downstream signaling through phosphorylation of its cytoplasmic tail. Previous studies have demonstrated that MUC1 alters expression of known targets of activator protein 1 (AP-1); however, no studies have evaluated the precise impact of MUC1 signaling on the activity and formation of AP-1. Given the known role of these proteins in modulating migration, invasion, and tumor progression, we explored the effects of MUC1 on AP-1 dimer formation and function. We determined that MUC1 increased the protein levels of c-Jun, the major component of AP-1, and promoted dimerization of c-Jun with the Fos-protein FRA-1. We demonstrate that FRA-1 acts as a potent mediator of migration and invasion in a manner that is modulated by signals through MUC1, which acts as a dominant regulator of specific AP-1 and FRA-1 target genes. Our results provide the first in vivo evidence of a FRA-1 mediated expression profile that impacts pancreatic tumor growth properties. In summary, we show that MUC1 enhancement of ERK activation influences FRA-1 activity to modulate tumor migration, invasion and metastasis in a subset of pancreatic cancer cases.

Original languageEnglish (US)
Pages (from-to)39996-40011
Number of pages16
JournalOncotarget
Volume7
Issue number26
DOIs
StatePublished - Jan 1 2016

Fingerprint

Proto-Oncogene Proteins c-fos
Transcription Factor AP-1
Pancreatic Neoplasms
Neoplasms
Proto-Oncogene Proteins c-jun
Dimerization
Glycoproteins
Proteins
Adenocarcinoma
Phosphorylation
Neoplasm Metastasis
Growth
Genes

Keywords

  • ERK
  • FRA-1
  • Invasion
  • MUC1
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1 : ERK signaling axis. / Hanson, Ryan L.; Brown, Roger B.; Steele, Maria M.; Grandgenett, Paul M.; Grunkemeyer, James A.; Hollingsworth, Michael A.

In: Oncotarget, Vol. 7, No. 26, 01.01.2016, p. 39996-40011.

Research output: Contribution to journalArticle

Hanson, Ryan L. ; Brown, Roger B. ; Steele, Maria M. ; Grandgenett, Paul M. ; Grunkemeyer, James A. ; Hollingsworth, Michael A. / Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1 : ERK signaling axis. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 39996-40011.
@article{8e69614cb26c4dd389acc0f9c088fe76,
title = "Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis",
abstract = "The MUC1 glycoprotein is overexpressed and aberrantly glycosylated in >90{\%} of pancreatic ductal adenocarcinoma cases and impacts tumor progression by initiating downstream signaling through phosphorylation of its cytoplasmic tail. Previous studies have demonstrated that MUC1 alters expression of known targets of activator protein 1 (AP-1); however, no studies have evaluated the precise impact of MUC1 signaling on the activity and formation of AP-1. Given the known role of these proteins in modulating migration, invasion, and tumor progression, we explored the effects of MUC1 on AP-1 dimer formation and function. We determined that MUC1 increased the protein levels of c-Jun, the major component of AP-1, and promoted dimerization of c-Jun with the Fos-protein FRA-1. We demonstrate that FRA-1 acts as a potent mediator of migration and invasion in a manner that is modulated by signals through MUC1, which acts as a dominant regulator of specific AP-1 and FRA-1 target genes. Our results provide the first in vivo evidence of a FRA-1 mediated expression profile that impacts pancreatic tumor growth properties. In summary, we show that MUC1 enhancement of ERK activation influences FRA-1 activity to modulate tumor migration, invasion and metastasis in a subset of pancreatic cancer cases.",
keywords = "ERK, FRA-1, Invasion, MUC1, Pancreatic cancer",
author = "Hanson, {Ryan L.} and Brown, {Roger B.} and Steele, {Maria M.} and Grandgenett, {Paul M.} and Grunkemeyer, {James A.} and Hollingsworth, {Michael A}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9557",
language = "English (US)",
volume = "7",
pages = "39996--40011",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1

T2 - ERK signaling axis

AU - Hanson, Ryan L.

AU - Brown, Roger B.

AU - Steele, Maria M.

AU - Grandgenett, Paul M.

AU - Grunkemeyer, James A.

AU - Hollingsworth, Michael A

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The MUC1 glycoprotein is overexpressed and aberrantly glycosylated in >90% of pancreatic ductal adenocarcinoma cases and impacts tumor progression by initiating downstream signaling through phosphorylation of its cytoplasmic tail. Previous studies have demonstrated that MUC1 alters expression of known targets of activator protein 1 (AP-1); however, no studies have evaluated the precise impact of MUC1 signaling on the activity and formation of AP-1. Given the known role of these proteins in modulating migration, invasion, and tumor progression, we explored the effects of MUC1 on AP-1 dimer formation and function. We determined that MUC1 increased the protein levels of c-Jun, the major component of AP-1, and promoted dimerization of c-Jun with the Fos-protein FRA-1. We demonstrate that FRA-1 acts as a potent mediator of migration and invasion in a manner that is modulated by signals through MUC1, which acts as a dominant regulator of specific AP-1 and FRA-1 target genes. Our results provide the first in vivo evidence of a FRA-1 mediated expression profile that impacts pancreatic tumor growth properties. In summary, we show that MUC1 enhancement of ERK activation influences FRA-1 activity to modulate tumor migration, invasion and metastasis in a subset of pancreatic cancer cases.

AB - The MUC1 glycoprotein is overexpressed and aberrantly glycosylated in >90% of pancreatic ductal adenocarcinoma cases and impacts tumor progression by initiating downstream signaling through phosphorylation of its cytoplasmic tail. Previous studies have demonstrated that MUC1 alters expression of known targets of activator protein 1 (AP-1); however, no studies have evaluated the precise impact of MUC1 signaling on the activity and formation of AP-1. Given the known role of these proteins in modulating migration, invasion, and tumor progression, we explored the effects of MUC1 on AP-1 dimer formation and function. We determined that MUC1 increased the protein levels of c-Jun, the major component of AP-1, and promoted dimerization of c-Jun with the Fos-protein FRA-1. We demonstrate that FRA-1 acts as a potent mediator of migration and invasion in a manner that is modulated by signals through MUC1, which acts as a dominant regulator of specific AP-1 and FRA-1 target genes. Our results provide the first in vivo evidence of a FRA-1 mediated expression profile that impacts pancreatic tumor growth properties. In summary, we show that MUC1 enhancement of ERK activation influences FRA-1 activity to modulate tumor migration, invasion and metastasis in a subset of pancreatic cancer cases.

KW - ERK

KW - FRA-1

KW - Invasion

KW - MUC1

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84982950702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982950702&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9557

DO - 10.18632/oncotarget.9557

M3 - Article

C2 - 27220889

AN - SCOPUS:84982950702

VL - 7

SP - 39996

EP - 40011

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -